Alseroxylon
Rautensin, Rauwiloid (alseroxylon) is an unknown pharmaceutical. Alseroxylon was first approved as Rauwiloid on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Alseroxylon |
| INN | — |
| Description | Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension and angina pectoris and as a sedative in psychoses. It was at one time approved for use in the United States, but has since been discontinued.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 8001-95-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201454 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00386 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use